TodayIR: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK DJ EQS-News: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK EQS-News / 29/04/2021 / 12:16 UTC+8 Zhaoke Ophthalmology(6622) Successfully Listed on Main Board of SEHK [April 29, 2021, Hong Kong] Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.
About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide s shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.
Abu Dhabi Ports successfully issues $1 billion 10-year bond
ABU DHABI, 29th April, 2021 (WAM) Abu Dhabi Ports, rated A+ (stable) by S&P and A+ (stable) by Fitch, has successfully issued US$1 billion 10 year bonds ( The Notes ) under its recently established Euro Medium Term Note Programme ( EMTN Programme ), to be jointly listed on the London Stock Exchange (LSE) and Abu Dhabi Securities Exchange (ADX).
The issuance was more than 4.5 times over-subscribed at its peak. The Notes mature on 6 May 2031 and carry a coupon of 2.500% per annum. Proceeds will be used for general corporate purposes and debt refinancing. The settlement of the offering is expected to occur on 6 May 2021 and is subject to customary settlement conditions.
EQS-News: PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse
PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse
29.04.2021 / 07:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
Vestas celebrates key Saudi project construction milestone
RIYADH, 9 hours, 56 minutes ago The Ministry of Energy of Saudi Arabia commemorated the mid-way mark of the construction of the Dumat Al Jandal wind farm, the kingdom’s first utility-scale wind farm of more than 400MW capacity and the largest in the Middle East. Vestas, the energy industry’s global partner on sustainable energy solutions, is playing a vital role in the project, having installed half of the 99 V150-4.2MW wind turbines for the project. Located in the Al Jouf province, 900km north of Riyadh, the Dumat Al Jandal wind farm project was awarded to the consortium by the Renewable Energy Project Development Office (Repdo) of the Saudi Ministry of Energy, Industry and Mineral Resources (MEIM) in 2019.